With 5.39 million shares changed hands, the volume of the stock remained lighter than its average volume of 6.21 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.528 whereas the lowest price it dropped to was $0.385. The 52-week range on INDP shows that it touched its highest point at $2.42 and its lowest point at $0.27 during that stretch. It currently has a 1-year price target of $2.00. Beta for the stock currently stands at 1.58.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of INDP was up-trending over the past week, with a rise of 44.36%, but this was up by 18.71% over a month. Three-month performance dropped to -31.80% while six-month performance fell -50.59%. The stock lost -46.51% in the past year, while it has lost -80.59% so far this year. A look at the trailing 12-month EPS for INDP yields -1.49 with Next year EPS estimates of -0.90. For the next quarter, that number is -0.33. This implies an EPS growth rate of 16.15% for this year and 33.33% for next year. EPS is expected to grow by 18.55% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 57.27%.
Float and Shares Shorts:
At present, 16.03 million INDP shares are outstanding with a float of 12.90 million shares on hand for trading. On 2025-05-30, short shares totaled 1.02 million, which was 639.0 higher than short shares on 1745971200. In addition to Mr. Jeffrey A. Meckler J.D. as the firm’s CEO & Director, Dr. Michael J. Newman Ph.D. serves as its Founder, Chief Scientific Officer & Director.
Institutional Ownership:
Through their ownership of 0.13085 of INDP’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, INDP reported revenue of $0.0 and operating income of -$4572559.0. The EBITDA in the recently reported quarter was -$4572559.0 and diluted EPS was -$0.32.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With INDP analysts setting a high price target of 2.0 and a low target of 2.0, the average target price over the next 12 months is 2.0. Based on these targets, INDP could surge 344.44% to reach the target high and rise by 344.44% to reach the target low. Reaching the average price target will result in a growth of 344.44% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$1.71 being high and -$1.71 being low. For INDP, this leads to a yearly average estimate of -$1.71.
